We are live on
!
Find out more
VAM
Visium Asset Management Portfolio holdings
AUM
$1.43B
1-Year Est. Return
3.58%
This Fund
S&P 500
This Quarter
Est. Return
-12.03%
1 Year Est. Return
-3.58%
3 Year Est. Return
+100.3%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$7.32B
AUM Growth
+$267M
(+3.8%)
Cap. Flow
+$1.37B
Cap. Flow
% of AUM
18.68%
Top 10 Holdings %
Top 10 Hldgs %
27.6%
Holding
1,433
New
327
Increased
283
Reduced
238
Closed
555
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$306M |
| 2 |
Cigna
CI
|
+$151M |
| 3 |
Pacira BioSciences
PCRX
|
+$143M |
| 4 |
ENDP
Endo International plc
ENDP
|
+$120M |
| 5 |
Tenet Healthcare
THC
|
+$99.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ESPR
Esperion Therapeutics
ESPR
|
+$64.7M |
| 2 |
BCR
CR Bard Inc.
BCR
|
+$62.4M |
| 3 |
Perrigo
PRGO
|
+$52.7M |
| 4 |
RCPT
RECEPTOS INC COM STK (DE)
RCPT
|
+$49.4M |
| 5 |
SKX
Skechers
SKX
|
+$47.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 50.8% |
| 2 | Financials | 7.09% |
| 3 | Consumer Discretionary | 5.97% |
| 4 | Energy | 5.17% |
| 5 | Industrials | 4.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Freeport-McMoran
FCX
$90B
| $10.6M | 0.14% |
1,092,000
+713,021
| +188% | +$8.55M |
|
152
BWX Technologies
BWXT
$15.5B
| $10.5M | 0.14% |
+399,900
| New | +$10.2M |
|
|
PFPT
153
DELISTED
Proofpoint, Inc.
PFPT
| $10.5M | 0.14% |
174,776
+116,596
| +200% | +$7.24M |
|
154
Aramark
ARMK
$15B
| $10.5M | 0.14% |
490,588
-42,637
| -8% | -$974K |
|
|
NVRO
155
DELISTED
NEVRO CORP.
NVRO
| $10.5M | 0.14% |
225,419
-24,881
| -10% | -$1.21M |
|
|
BHI
156
PUT
DELISTED
Baker Hughes
BHI
| $10.4M | 0.14% |
+200,000
| New | +$11.2M |
|
157
PUT
Micron Technology
MU
$930B
| $10.3M | 0.14% |
+690,500
| New | +$11.9M |
|
158
KLA
KLAC
$239B
| $10.3M | 0.14% |
+2,058,000
| New | +$10.6M |
|
159
CALL
Amazon
AMZN
$2.92T
| $10.2M | 0.14% |
+400,000
| New | +$10.1M |
|
160
Charles River Laboratories
CRL
$11.2B
| $10.1M | 0.14% |
+159,413
| New | +$11.4M |
|
|
FLOW
161
DELISTED
SPX FLOW, Inc.
FLOW
| $10M | 0.14% |
+290,573
| New | +$9.88M |
|
162
PUT
Transocean
RIG
$5.89B
| $9.95M | 0.14% |
770,000
+762,300
| +9,900% | +$10.6M |
|
163
Vulcan Materials
VMC
$34.8B
| $9.81M | 0.13% |
110,000
+106,170
| +2,772% | +$9.89M |
|
|
TWX
164
DELISTED
Time Warner Inc
TWX
| $9.74M | 0.13% |
141,677
-11,961
| -8% | -$940K |
|
165
HP
HPQ
$24.9B
| $9.71M | 0.13% |
834,556
+363,746
| +77% | +$4.72M |
|
|
166
PUT
Freeport-McMoran
FCX
$90B
| $9.69M | 0.13% |
1,000,000
+994,500
| +18,082% | +$11.9M |
|
167
Vale
VALE
$64.1B
| $9.66M | 0.13% |
+2,300,000
| New | +$11.7M |
|
|
AMSGP
168
DELISTED
Amsurg Corp. 5.25% Mandatory Convertible Pft Stk Ser A-1
AMSGP
| $9.66M | 0.13% |
+65,000
| New | +$9.86M |
|
169
Burlington
BURL
$23.2B
| $9.63M | 0.13% |
188,788
-61,512
| -25% | -$3.28M |
|
|
IMPV
170
DELISTED
Imperva, Inc.
IMPV
| $9.51M | 0.13% |
145,300
+141,110
| +3,368% | +$9.36M |
|
171
Hanover Insurance
THG
$8.1B
| $9.42M | 0.13% |
+121,195
| New | +$9.6M |
|
|
CMCSK
172
DELISTED
COMCAST CORP SPL A (NEW)
CMCSK
| $9.4M | 0.13% |
164,256
+96,700
| +143% | +$5.54M |
|
173
Cabot Corp
CBT
$4.54B
| $9.37M | 0.13% |
296,767
+27,670
| +10% | +$959K |
|
174
Encompass Health
EHC
$11B
| $9.26M | 0.13% |
303,351
+297,423
| +5,017% | +$10.4M |
|
175
CALL
McKesson
MCK
$100B
| $9.25M | 0.13% |
+50,000
| New | +$10.6M |
|
Similar funds
FBNAT
CPS
LH
CPM
VFS
ZA
FVFIGP
WA
Visium Asset Management's Q3 2015 Portfolio in Review
As of Q3 2015, Visium Asset Management held 1,433 positions worth $7.32B, up 3.8% from $7.05B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Visium Asset Management deployed $1.37B of net new capital in Q3 2015, opening 327 new positions and adding to 283 existing holdings. Its largest new stake was Allergan plc: 997,201 shares worth $271M.
By sector, the portfolio is most concentrated in Healthcare at 51% of assets, up from 49% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was Perrigo, an estimated $52.7M trimmed.
- Visium Asset Management's largest Q3 2015 buy was Allergan plc: 997,201 shares worth $271M.
- Visium Asset Management added most to Pacira BioSciences in Q3 2015, an estimated $143M increase.
- Visium Asset Management's biggest Q3 2015 reduction was Perrigo, cutting an estimated $52.7M.
- Visium Asset Management fully exited Esperion Therapeutics in Q3 2015, selling an estimated $64.7M.
- Visium Asset Management's ten largest holdings make up 28% of its $7.32B portfolio in Q3 2015.
- Visium Asset Management opened 327 new positions and closed 555 in Q3 2015.
- Visium Asset Management's portfolio value rose 3.8% quarter-over-quarter to $7.32B.
Based on Visium Asset Management's 13F filing for Q3 2015, filed 16 Nov 2015.